 Definition of genetic testing

 Purpose of genetic testing

 Types of genetic testing

 Basis of genetic testing

 Prenatal diagnosis and screening

 Common diagnostic test

 Techniques for pathological examination

 Ethical legal and psychosocial issue in

genetic testing
 Finding genetic disease in unborn child
 Finding out if people carry genes for a disease and
might pass it on to their children.
 Screening embryos for disease.

 Testing for genetic disease in adult before they cause

symptoms.
 Making a diagnosis in a person who has disease
symptoms
 Figuring out the type or dose of a medicine that is
best for a certain person.
 Genetic testing is defined as “examining a sample of
blood or other body fluids or tissue for bio-chemical
chromosomal, or genetic markers that indicate the
presence or absence of genetic disease.
 A genetic testing is analyzing a DNA to look for

genetic alteration that may indicate an increased risk
for developing a specific disease or disorder.

Or

 It is also defined as type of medical test, identifies

changes in chromosomes, genes or proteins.
 Carrier screening which involves identifying unaffected
individuals who carry one copy for the disease to be
expressed.

 Pre implantation genetic diagnosis.

 Pre natal diagnostic testing.

 New born screening

 Pre symptomatic testing for estimating the risk of adult

onset cancer and alziemer’s disease
 Conformational diagnosis of a
symptomatic individual.
 Forensic or identity testing.

 Pre symptomatic testing for predicting adult onset

disorders such as Huntington’s chorea.
 It allows the genetic disorder of vulnerabilities to
inherited diseases.
 It can be used to determine a child potentiality or
person ancestry.
 Quantitative genetic research has built a strong case for the
importance of genetic factor in many complex behavioural
disorder and dimensions in the domains of psychopathology,
personality and cognitive abilities.

 The genetic basis of behavioural disorder has largely relied on

a reductionist one gene one disorder (ONOD) approach in
which a single gene is necessary and sufficient to develop a
disorder.

 In contrast a quantitative trait loci approach involves the

search for multiple genes.
 Managing the remaining weeks of the pregnancy
 Determining the outcome of the pregnancy

 Planning for possible complications with birth

the process
 Planning for problems that may occur in the newborn
infant
 Deciding whether to continue the pregnancy

 Finding conditions that may affect future pregnancies.

 This is a non-invasive procedure that is harmless to both the
fetus and the mother.

 The developing embryo can first be visualized at about 6 weeks

gestation.

 Recognition of the major internal organs and extremities to

determine if any abnormality can best be accomplished
between 16 to 20 weeks gestation.
 the size and position of the fetus,

 the size and position of the placenta,

 the amount of amniotic fluid,

 the appearance of fetal anatomy,

 Abnormalities may not be detected until later in pregnancy, or
may not be detected at all.
 A good example of this is Down syndrome (trisomy 21) where
the morphologic abnormalities are often not marked,
 This is an invasive procedure .
 Amniocenteses are between 14 and 20
performed weeks gestation.
 An ultrasound examination always
precedes amniocentesis
 In the third trimester of pregnancy, the amniotic fluid can be
analyzed for determination of fetal lung maturity
 amniotic fluid can be analyzed for
lecithin:sphingomyelin (LS) ratio, and/or for phosphatidyl
glycerol (PG).
 fetal loss (0.5%)
 maternal Rh sensitization.

 If oligohydramnios is present, then amniotic fluid

cannot be obtained.
 CVS can be safely performed between 9.5 and 12.5 weeks
gestation.

 In this procedure, a catheter is passed via the vagina through the

cervix and into the uterus to the developing placenta under
ultrasound guidance

 The introduction of the catheter allows sampling of

cells
from the placental chorionic villi.

 These cells can then be analyzed by variety of techniques. The

most common test employed on cells obtained by CVS is
chromosome analysis to determine the karyotype of the fetus.
 This is a new technique that makes use of the phenomenon of fetal
blood cells gaining access to maternal circulation through the
placental villi.

 The fetal cells can be sorted out and analyzed by a variety of

techniques to look for particular DNA sequences

 Fluorescence in-situ hybridization (FISH) is one technique that

can be applied to identify particular chromosomes of the fetal cells
recovered from maternal blood and diagnose aneuploid condition
such as the trisomies and monosomy X.
 It is difficult to get many fetal blood cells.
 There may not be enough to reliably determine anomalies of
the fetal karyotype or assay for other abnormalities.
 The developing fetus has two major blood
proteins- albumin and alpha-fetoprotein (AFP).

 The MSAFP test can be utilized to determine the levels of

AFP from the fetus

 Ordinarily, only a small amount of AFP gains access to the

amniotic fluid and crosses the placenta to mother's blood.
 When there is a neural tube defect in the fetus,

 Then there is a means for escape of more AFP into the

amniotic fluid.
 The AFP from the fetus will end up in maternal blood in
higher amounts.
 Neural tube defects include anencephaly and spina bifida .
 This test is most commonly used as a test for pregnancy.

 The beta-HCG can also be quantified in serum from maternal

blood, and this can be useful early in pregnancy when
threatened abortion or ectopic pregnancy suspected

 because the amount of beta-HCG will be lower than expected.

 An elevated beta-HCG coupled with a decreased MSAFP
suggests Down syndrome.

 Very high levels of HCG suggest trophoblastic disease (molar

pregnancy).

 The absence of a fetus on ultrasonography along with an

elevated HCG suggests a hydatidiform mole

 The HCG level can be used to follow up treatment for molar

pregnancy to make sure that no trophoblastic disease, such as a
choriocarcinoma, persists.
 The amount of estriol in maternal serum is
dependent upon a viable fetus, a properly
functioning placenta, and maternal well-being.

substrate for estriol begins as dehydroepiandrosterone

(DHEA) made by the fetal adrenal glands

This is further metabolized in the placenta to

estriol.
 The estriol crosses to the maternal circulation and is
excreted by the maternal kidney in urine or by the
maternal liver in the bile

 The measurement of serial estriol levels in the third

trimester will give an indication of general well-being of
the fetus

 If the estriol level drops, then the fetus is

threatened
and delivery may be necessary emergently

 Estriol tends to be lower when Down syndrome is

present and when there is adrenal hypoplasia with
anencephaly.
 Inhibin is secreted by the placenta and the corpus luteum.

 Inhibin –A is associated with an increased risk of trisomy 21,

 A high inhibin –A may be associated with a risk for preterm

delivery.
 Low levels of PAPP-A as measured in maternal serum
during the first trimester may be associated with fetal
chromosomal anomalies including trisomies 13, 18, and
21

 Low PAPP-A levels in the first trimester may predict

an adverse pregnancy outcome, including a small for
gestational age (SGA) baby or stillbirth.

A high PAPP-A level may predict a large for gestational

age (LGA) baby.
 Combining the maternal serum assays may aid in increasing
the sensitivity and specificity of detection for fetal
abnormalities.

 The classic test is the triple screen for alpha-fetoprotein

(MSAFP), beta-HCG, and estriol (uE3). The "quadruple
screen" adds inhibin-A.
 It is useful in detecting gross fetal parts.

 The pattern of gross abnormalities can often suggest

a possible chromosomal abnormality or a syndrome.

 Consultations are obtained with clinical geneticists

to
review the findings

 Examination of the placenta is very important, because the

reason for the fetal loss may be a placental problem
 Microscopic examination of the placenta is
important

Microscopy can aid in determination of

gestational age (lung, kidney
maturity), presence of infection, presence of
neoplasia, or presence of "dysplasia" (abnormal
organogenesis).
 Radiographic views are essential for analysis
of the fetal skeleton.

 Radiographs are useful for comparison

prenatal ultrasound, and with help define
when autopsy consent is limitedanomalies

 To determine sites to be examined microscopically.

 Skeletal anomalies (dwarfism, dysplasia, etc.)

 Neural tube defects (anencephaly, spina bifida, etc.)

 Osteogenesis imperfecta

 Soft tissue changes (hydrops, hygroma, etc.)

 Teratomas or other neoplasms

 Growth retardation

 Orientation and audit of fetal parts

 Assessment of catheter or therapeutic device placement

 Culture can aid in diagnosis or confirmation of congenital
infections:-
 T - toxoplasmosis

 O - other, such as Listeria monocytogenes, group

B streptococcus, syphilis
 R - rubella

 C - cytomegalovirus

 H - herpes simplex or human immunodeficiency virus

(HIV)
 Tissues must be obtained as fresh as possible for culture and
without contamination.

 A useful procedure is to wash the tissue samples in sterile

saline prior to placing them into cell culture media.

 Tissues with the best culture for growth are those with the least
maceration: placenta, lung, and diaphragm.

 Obtaining tissue from more than one site can increase the yield
by avoiding contamination or by detection of mosaicism.
 Patient need to sufficiently informed about the implication of
genetic screening before they can provide informed consent.

 The public view genetic with a sense of inevitability. However, a

genetic condition alone may modify risks from environmental or
life style factor.

The voluntary nature of the

screening process must be
emphasized.
 To potential psychological distress, counseling
reduce
should be available to provide information about genetic risk
and explain choices regarding genetic testing and further
management.

 Support is needed for individuals who need to consider issue

such as stigma disclosure to family members and confidentiality.
 Couple known to carry a recessive or dominance single gene
defect or sex linked condition need counseling about their
reproductive option. This may include prenatal diagnosis and
possible pregnancy termination in the case of an affected fetus
and pre-implantation genetic diagnosis.
The public’s understanding of genetic may be
limited and can lead to sigma.

 Misunderstanding of the genetic risk

can increase stigmatization.
of developing disease This may be around
expectancy, lifestyle choices, or decision
life about
children. having

 Identification of a genetic condition before birth raises issue of

whether the parents wish to terminate the pregnancy. Some
commentators have argues that the ability to only select perfect
babies is a form of eugenesis.
 Confidentiality

 Like other medical information, result from genetic testing are

considered confidential, under normal practice, the doctor
patient relationship protect against disclosure of genetic
information.

 However there is less

clarity where relativewish to
know the result of a
family member’s genetic test, as it may have
direct relevance for them.
 Another particular dilemma is the case of a pregnant woman
wanting to know the result of a test taken by the baby’s
father.

 The storage of genetic screening data and registries of

patients creates particular concern, given that the results may
impact
negatively on family
members.
 Doctors face a dilemma when reporting the results of genetic
screening. Standard medical practice is based on the principles
that doctor’s should focus on their patient and that medical
information should remain confidential.

 It is unclear if doctors are ethically permitted to inform relatives

in cases when the result of genetic test indicates real risk to their
health.
 Doctors may also be faced with a decision about whether to
persuade patient about the need to disclose their test result to
relatives.

 Although most professional bodies that disclosure should

not be against the right of relatives have won priorities.
 The primary concerns among the public is the use of genetic
information to delay access to health insurance or medical
treatment.

 Conversely health insurance claim right to access such data

where it exist to avoid the moral hazards of patient with
known condition taking out an insurance policy without
disclosing this information.
 Dutta D. C. “ textbook of obstetrics” 6th edition, new central book agency (p)
limited, 2009.
 Gangane S. D. “human genetics” 3rd edition, Elsevier publishers, 2010.
 Mandal Sanjay “ fundamentals of human genetics” 2nd edition, New Central
BBook agency, Page no. 209-212.
 Perry, Lsowdermilk, “Maternity and women’s health care” 8th edition, mosby an
affiliated
by Elsevier page no. 67-69.
 Sharma, Kumar Suresh, “human genetics in nursing, 2nd edition, Jaypee
Publishers, 2011

 Internet-
www.wikepedia.com
www.sparknotes.com
www.slideshare.com
www.pubmed.com
www.nsgc.org
www.geneticalliance.org

 Dictionary –
Oxford essential dictionary.
For learners of English,
oxford university press.